2023 Fiscal Year Final Research Report
Beyond Steroids: Toward the Development of Novel Therapies for Autoimmune Diseases.
| Project/Area Number |
22K19428
|
|---|
| Research Category |
Grant-in-Aid for Challenging Research (Exploratory)
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Medium-sized Section 49:Pathology, infection/immunology, and related fields
|
|---|
| Research Institution | Shiga University of Medical Science |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2022-06-30 – 2024-03-31
|
| Keywords | 自己免疫疾患 / ステロイド / ナルディライジン |
|---|
| Outline of Final Research Achievements |
Diseases caused by autoimmune mechanisms include many diseases for which effective treatments are scarce and steroids are the only therapeutic agents. We investigated the potential of nardilysin (NRDC)-targeted therapies as an alternative to steroids, as mouse deficient in NRDC (NRDC-KO) conferred disease resistance in several inflammatory models. In this study, we used T- and B-cell-specific deficient mice and showed that NRDC expressed in lymphocytes may play an important role in the pathogenesis of several autoimmune diseases (autoimmune hepatitis and systemic lupus erythematosus).
|
| Free Research Field |
病態医化学 薬理学 内科学
|
| Academic Significance and Societal Importance of the Research Achievements |
我が国では、原因不明、治療方針が未確定で後遺症を残すおそれが少なくない300以上の疾患を指定難病と認定してます。その中には自己免疫機序を原因とし、ステロイドが唯一の治療薬である疾患が多く含まれていますが、ステロイドの長期内服が必要な患者は、その重篤な副作用に苦しめられています。我々は、ナルディライジン（NRDC）という分子を欠損したマウスを用い研究を行い、この分子を抑制することが新たな自己免疫性疾患治療薬開発につながる可能性を示しました。今後もNRDCを標的とする治療薬がステロイドの代替となる可能性を追求します。
|
